Sanofi SA
SNY52.770USD
+0.920+1.77%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
132.30BMarktkapitalisierung
21.86KGV TTM
mehr Informationen über Sanofi SA Unternehmen
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Unternehmensinformationen
Unternehmens-codeSNY
Name des UnternehmensSanofi SA
IPO-datumJul 01, 2002
Gegründet am1994
CEOMr. Paul Hudson, Ph.D.
Anzahl der mitarbeiter84587
WertpapierartDepository Receipt
GeschäftsjahresendeJul 01
Addresse46 Avenue de la Grande Armee
StadtPARIS
BörseNASDAQ Global Select Consolidated
LandFrance
Postleitzahl75017
Telefon33153774000
Websitehttps://www.sanofi.com/
Unternehmens-codeSNY
IPO-datumJul 01, 2002
Gegründet am1994
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Independent Director
--
--
Ms. Madeleine Roach
Ms. Madeleine Roach
Executive Vice President - Business Operations, Member of the Executive Committee
Executive Vice President - Business Operations, Member of the Executive Committee
--
--
Mr. Christophe Babule
Mr. Christophe Babule
Director
Director
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Audrey Duval Derveloy
Ms. Audrey Duval Derveloy
Executive Vice President - Corporate Affairs, Member of the Executive Committee
Executive Vice President - Corporate Affairs, Member of the Executive Committee
--
--
Mr. Roy Papatheodorou
Mr. Roy Papatheodorou
Executive Vice President, General Counsel, Member of the Executive Committee
Executive Vice President, General Counsel, Member of the Executive Committee
--
--
Mr. John Sundy
Mr. John Sundy
Independent Director
Independent Director
--
--
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Prof. Dr. Houman Ashrafian, M.D., Ph.D.
Prof. Dr. Houman Ashrafian, M.D., Ph.D.
Executive Vice President, Head of Research and Development, Member of the Executive Committee
Executive Vice President, Head of Research and Development, Member of the Executive Committee
--
--
Mr. Brian Foard
Mr. Brian Foard
Executive Vice President - Specialty Care, Member of the Executive Committee
Executive Vice President - Specialty Care, Member of the Executive Committee
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Independent Director
--
--
Ms. Madeleine Roach
Ms. Madeleine Roach
Executive Vice President - Business Operations, Member of the Executive Committee
Executive Vice President - Business Operations, Member of the Executive Committee
--
--
Mr. Christophe Babule
Mr. Christophe Babule
Director
Director
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Audrey Duval Derveloy
Ms. Audrey Duval Derveloy
Executive Vice President - Corporate Affairs, Member of the Executive Committee
Executive Vice President - Corporate Affairs, Member of the Executive Committee
--
--
Mr. Roy Papatheodorou
Mr. Roy Papatheodorou
Executive Vice President, General Counsel, Member of the Executive Committee
Executive Vice President, General Counsel, Member of the Executive Committee
--
--
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Dupixent
14.14B
31.82%
Polio / Pertrussis / Hib
2.96B
6.67%
Meningitis, Travel and endemic vaccines
1.82B
4.10%
Booster vaccines
1.42B
3.20%
Alltuviio
737.64M
1.66%
Other
23.34B
52.54%
Nach RegionUSD
Name
Umsatz
Anteil
United States
21.62B
48.65%
Rest of the World (Japan, South Korea, Canada, Australia, New Zealand)
13.05B
29.38%
Europe excl. France
7.80B
17.56%
France
1.96B
4.42%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Dupixent
14.14B
31.82%
Polio / Pertrussis / Hib
2.96B
6.67%
Meningitis, Travel and endemic vaccines
1.82B
4.10%
Booster vaccines
1.42B
3.20%
Alltuviio
737.64M
1.66%
Other
23.34B
52.54%
Aktionäre
Update-Zeit: Fri, Apr 18
Update-Zeit: Fri, Apr 18
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Dodge & Cox
2.98%
Fisher Investments
0.50%
Invesco Advisers, Inc.
0.45%
T. Rowe Price Associates, Inc.
0.43%
Capital World Investors
0.32%
Other
95.32%
Aktionärsstatistik
Aktionäre
Anteil
Dodge & Cox
2.98%
Fisher Investments
0.50%
Invesco Advisers, Inc.
0.45%
T. Rowe Price Associates, Inc.
0.43%
Capital World Investors
0.32%
Other
95.32%
Art
Aktionäre
Anteil
Investment Advisor/Hedge Fund
5.58%
Investment Advisor
4.17%
Research Firm
0.78%
Hedge Fund
0.29%
Bank and Trust
0.07%
Pension Fund
0.02%
Family Office
0.01%
Other
89.08%
Institutionelle Beteiligung
Update-Zeit: Sun, Jan 19
Update-Zeit: Sun, Jan 19
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
1224
270.71M
10.71%
-28.06M
2024Q4
1263
270.44M
10.70%
-30.67M
2024Q3
1239
286.03M
11.43%
-5.72M
2024Q2
1248
275.46M
11.01%
-5.50M
2024Q1
1232
261.25M
10.33%
-7.62M
2023Q4
1213
251.25M
9.93%
-18.33M
2023Q3
1178
256.18M
10.15%
-15.97M
2023Q2
1173
257.65M
10.20%
-26.92M
2023Q1
1174
268.83M
10.66%
-6.19M
2022Q4
1167
264.16M
10.47%
-6.09M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Dodge & Cox
75.22M
2.98%
-1.08M
-1.41%
Dec 31, 2024
Fisher Investments
12.51M
0.5%
-848.08K
-6.35%
Dec 31, 2024
Invesco Advisers, Inc.
11.37M
0.45%
+303.99K
+2.75%
Dec 31, 2024
T. Rowe Price Associates, Inc.
10.84M
0.43%
+5.09M
+88.50%
Dec 31, 2024
Managed Account Advisors LLC
7.74M
0.31%
-611.48K
-7.32%
Dec 31, 2024
Barrow Hanley Global Investors
7.70M
0.3%
-140.54K
-1.79%
Dec 31, 2024
Boston Partners
5.40M
0.21%
+2.50M
+86.38%
Dec 31, 2024
Fidelity Management & Research Company LLC
4.95M
0.2%
-3.65M
-42.49%
Dec 31, 2024
Wellington Management Company, LLP
4.48M
0.18%
-166.02K
-3.57%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
VanEck Pharmaceutical ETF
5.04%
Invesco International Dividend Achievers ETF
3.48%
Putnam Focused Large Cap Value ETF
2.86%
Pacer Global Cash Cows Dividend ETF
2.16%
Brandes US Value ETF
2.03%
Altrius Global Dividend ETF
1.99%
Pacer Trendpilot European Index ETF
1.95%
ProShares Ultra Nasdaq Biotechnology
1.59%
Invesco Nasdaq Biotechnology ETF
1.57%
Simplify Health Care ETF
1.57%
Mehr Anzeigen
VanEck Pharmaceutical ETF
Anteil5.04%
Invesco International Dividend Achievers ETF
Anteil3.48%
Putnam Focused Large Cap Value ETF
Anteil2.86%
Pacer Global Cash Cows Dividend ETF
Anteil2.16%
Brandes US Value ETF
Anteil2.03%
Altrius Global Dividend ETF
Anteil1.99%
Pacer Trendpilot European Index ETF
Anteil1.95%
ProShares Ultra Nasdaq Biotechnology
Anteil1.59%
Invesco Nasdaq Biotechnology ETF
Anteil1.57%
Simplify Health Care ETF
Anteil1.57%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
23.51B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Mar 26, 2024
SNY.NB Final Cash Dividend of gross USD 2.036908 paid on Jun 06, 2024 going ex on May 09, 2024
May 10, 2024
Jun 06, 2024
May 09, 2024
Feb 15, 2023
SNY.NB Final Cash Dividend of gross USD 1.900085 paid on Jun 23, 2023 going ex on May 30, 2023
May 31, 2023
Jun 23, 2023
May 30, 2023
Apr 20, 2022
SNY.NB Final Cash Dividend of gross USD 1.74684 paid on May 31, 2022 going ex on May 04, 2022
May 05, 2022
May 31, 2022
May 04, 2022
Mar 24, 2021
SNY.NB Final Cash Dividend of gross USD 1.928784 paid on May 26, 2021 going ex on May 03, 2021
May 04, 2021
May 26, 2021
May 03, 2021
Mar 05, 2020
SNY.NB Final Cash Dividend of gross USD 1.699399 paid on May 26, 2020 going ex on Apr 30, 2020
May 01, 2020
May 26, 2020
Apr 30, 2020
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten